Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies

Atherosclerosis

Volumn 245, Issue , 2016, Pages 143-154

  Kunutsor, Setor K ^a   Bakker, Stephan J L ^b   James, Richard W ^c   Dullaart, Robin P F ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cardiovascular disease; Meta analysis; Paraoxonase 1; Risk factor; Risk prediction

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FOLLOW UP; HAZARD RATIO; HUMAN; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASES; ENZYMOLOGY; GLOBAL HEALTH; HEALTH SURVEY; META ANALYSIS; MORBIDITY; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR; TRENDS;

ARYLDIALKYLPHOSPHATASE; BIOMARKERS; CARDIOVASCULAR DISEASES; GLOBAL HEALTH; HUMANS; MORBIDITY; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84951754179     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.12.021     Document Type: Article

References (64)

1. Prospective Studies Collaboration, Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
2. Triolo M., Annema W., Dullaart R.P., et al. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomarkers Med. 2013, 7:457-472.
3. Andrews K.L., Moore X.L., Chin-Dusting J.P. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium. Clin. Exp. Pharmacol. physiology 2010, 37:736-742.
4. Meurs I., Van Eck M., Van Berkel T.J. High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr. Pharm. Des. 2010, 16:1445-1467.
5. Podrez E.A. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. physiology 2010, 37:719-725.
6. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 2006, 58:342-374.
7. Deakin S.P., James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond) 2004, 107:435-447.
8. Karabina S.A., Lehner A.N., Frank E., et al. Oxidative inactivation of paraoxonase-implications in diabetes mellitus and atherosclerosis. Biochimica biophysica acta 2005, 1725:213-221.
9. Mackness M.I., Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991, 86:193-199.
10. Graner M., James R.W., Kahri J., et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J. Am. Coll. Cardiol. 2006, 47:2429-2435.
11. Dullaart R.P., de Vries R., Sluiter W.J., et al. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin. Endocrinol. 2009, 70:221-226.
12. Zhao Y., Ma Y., Fang Y., et al. Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies. Mol. Genet. metabolism 2012, 105:141-148.
13. Wang M., Lang X., Cui S., et al. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk. DNA cell Biol. 2012, 31:975-982.
14. Bhattacharyya T., Nicholls S.J., Topol E.J., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA J. Am. Med. Assoc. 2008, 299:1265-1276.
15. Birjmohun R.S., Vergeer M., Stroes E.S., et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk prospective population Study. PloS one 2009, 4:e6809.
16. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the caerphilly prospective Study. Circulation 2003, 107:2775-2779.
17. Tang W.H., Hartiala J., Fan Y., et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arteriosclerosis, thrombosis, Vasc. Biol. 2012, 32:2803-2812.
18. Ikeda Y., Inoue M., Suehiro T., et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta diabetol. 2009, 46:239-242.
19. Ikeda Y., Suehiro T., Itahara T., et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin. Nephrol. 2007, 67:358-365.
20. van Himbergen T.M., van der Schouw Y.T., Voorbij H.A., et al. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 2008, 199:408-414.
21. Troughton J.A., Woodside J.V., Yarnell J.W., et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 2008, 197:556-563.
22. Patra S.K., Singh K., Singh R. Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus. Diabetes & metabolic syndrome 2013, 7:108-111.
23. Lambers Heerspink H.J., Brantsma A.H., de Zeeuw D., et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am. J. Epidemiol. 2008, 168:897-905.
24. Richter R.J., Jarvik G.P., Furlong C.E. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol. Appl. Pharmacol. 2009, 235:1-9.
25. van Himbergen T.M., Roest M., de Graaf J., et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. lipid Res. 2005, 46:445-451.
26. Deakin S., Moren X., James R.W. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005, 179:17-25.
27. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur. heart J. 2007, 28:1012-1018.
28. Dullaart R.P., Perton F., van der Klauw M.M., et al. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010, 208:537-542.
29. Corsetti J.P., Bakker S.J., Sparks C.E., et al. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. PloS one 2012, 7:e39110.
30. Kunutsor S.K., Bakker S.J., Kootstra-Ros J.E., et al. Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: the PREVEND study. Atherosclerosis 2015, 243:138-147.
31. Kunutsor S.K., Bakker S.J., Kootstra-Ros J.E., et al. Serum alkaline phosphatase and risk of incident cardiovascular disease: Interrelationship with high sensitivity C-reactive protein. PloS one 2015, 10:e0132822.
32. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 2012, 367:20-29.
33. Kunutsor S.K., Bakker S.J., Kootstra-Ros J.E., et al. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis 2014, 238:356-364.
34. Stricker B.H., Herings R.M. Plea for the retention of the Dutch National Medical Registration (LMR) to provide reliable information regarding public health and healthcare. Ned. Tijdschr. Geneeskd. 2006, 150:1916-1917.
35. Therneau T.M., Grambsch P.M. Modeling Survival Data: Extending the Cox Model 2000, Springer, New York.
36. Easton D.F., Peto J., Babiker A.G. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat. Med. 1991, 10:1025-1035.
37. Horsfall L.J., Nazareth I., Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012, 126:2556-2564.
38. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15:361-387.
39. Greenland P., Alpert J.S., Beller G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American college of cardiology foundation/American heart association task force on practice Guidelines. Circulation 2010, 122:e584-636.
40. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham heart Study. Circulation 2008, 117:743-753.
41. Pencina M.J., D'Agostino R.B., D'Agostino R.B., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 2008, 27:157-172. discussion 207-112.
42. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of Cardiology/American heart Association task force on practice Guidelines. J. Am. Coll. Cardiol. 2014, 63:2889-2934.
43. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk Score. JAMA J. Am. Med. Assoc. 2007, 297:611-619.
44. Ridker P.M., Paynter N.P., Rifai N., et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation 2008, 118:2243-2251. 2244pp. following 2251.
45. Kunutsor S.K., Apekey T.A., Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis 2014, 236:7-17.
46. Wells G.A., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses 2011, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
47. Chêne G., Thompson S.G. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am. J. Epidemiol. 1996, 144:610-621.
48. Greenland S., Longnecker M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am. J. Epidemiol. 1992, 135:1301-1309.
49. Woodward M., Barzi F., Feigin V., et al. Associations between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. Eur. heart J. 2007, 28:2653-2660.
50. Blatter M.C., James R.W., Messmer S., et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. biochemistry/FEBS 1993, 211:871-879.
51. Mackness M.I., Hallam S.D., Peard T., et al. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp. Biochem. physiology. B, Comp. Biochem. 1985, 82:675-677.
52. Dullaart R.P., Kwakernaak A.J., Dallinga-Thie G.M. The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome. Atherosclerosis 2013, 230:6-11.
53. Dullaart R.P., Otvos J.D., James R.W. Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in type 2 diabetic and non-diabetic subjects. Clin. Biochem. 2014, 47:1022-1027.
54. Mackness M.I., Arrol S., Abbott C., et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
55. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989, 320:915-924.
56. Heinecke J.W., Lusis A.J. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis?. Am. J. Hum. Genet. 1998, 62:20-24.
57. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arteriosclerosis, thrombosis, Vasc. Biol. 2001, 21:473-480.
58. Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101:2510-2517.
59. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
60. Mackness B., Quarck R., Verreth W., et al. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arteriosclerosis, thrombosis, Vasc. Biol. 2006, 26:1545-1550.
61. Hayek T., Fuhrman B., Vaya J., et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arteriosclerosis, thrombosis, Vasc. Biol. 1997, 17:2744-2752.
62. Aviram M., Dornfeld L., Rosenblat M., et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr. 2000, 71:1062-1076.
63. Huen K., Richter R., Furlong C., et al. Validation of PON1 enzyme activity assays for longitudinal studies. Clin. Chim. Acta 2009, 402:67-74.
64. Blatter Garin M.C., Abbott C., Messmer S., et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem. J. 1994, 304(Pt 2):549-554.